Measurement of the platelet electrophoretic response to adenosine diphosphate (ADP) has been used to study platelets from two groups of patients thought to have coronary artery disease, and 4 a group of relatives of men who had suffered myocardial infarctions before the age of 45. Of 34 arterial disease platelet sensitivity to ADP is increased so that maximum platelet mobility is induced by o oos ,ug/ml, while the platelet sensitivity to noradrenaline is normal (Hampton and Mitchell, I966c). In these patients the change in platelet behaviour results from a disturbance of the plasma lipids, the nature of which has only partly been elucidated (Bolton, Hampton, and Mitchell, I967). A similar abnormality in the plasma lipids and the platelets has been described in women taking oral contraceptives (Bolton, Hampton, and Mitchell, i968), but it appears to be limited to these two situations. Pending the final clarification of the plasma lipid abnormality, observations of the platelet electrophoretic behaviour of patients with arterial disease have been extended, and a group of subjects whose coronary arteries were investigated by angiography has been studied.
Measurement of the platelet electrophoretic response to adenosine diphosphate (ADP) has been used to study platelets from two groups of patients thought to have coronary artery disease, and 4 a group of relatives of men who had suffered myocardial infarctions before the age of 45. Of 34 patients diagnosed by clinical, biochemical, and electrocardiographic criteria to have had myocardial infarctions, 32 ges in platelet mobility: the maximum mobility that can be induced is about io per cent above the control value and in healthy subjects this increase is induced by oos5 ,ug/ml of either ADP or noradrenaline (Hampton and Mitchell, I966a). In patients with any sort of acute illness the maximum increase in platelet mobility is induced by o*oos ,tg/ml (or less) of ADP or noradrenaline (Hampton and Mit- chell, I966b). In patients with atheromatous arterial disease platelet sensitivity to ADP is increased so that maximum platelet mobility is induced by o oos ,ug/ml, while the platelet sensitivity to noradrenaline is normal (Hampton and Mitchell, I966c). In these patients the change in platelet behaviour results from a disturbance of the plasma lipids, the nature of which has only partly been elucidated (Bolton, Hampton, and Mitchell, I967) . A similar abnormality in the plasma lipids and the platelets has been described in women taking oral contraceptives (Bolton, Hampton, and Mitchell, i968) , but it appears to be limited to these two situations. Pending the final clarification of the plasma lipid abnormality, observations of the platelet electrophoretic behaviour of patients with arterial disease have been extended, and a group of subjects whose coronary arteries were investigated by angiography has been studied. Observations have also been made of the platelet behaviour of a group of close relatives of patients who developed myocardial infarctions before the age of 45.
Methods
Blood was collected by clean venepuncture into plastic syringes, and 9 ml aliquots were transferred to siliconized centrifuge tubes containing I ml of 3-8 per cent (w/v) trisodium citrate. Platelet-rich plasma and platelet-poor plasma were prepared and the platelet-rich plasma was diluted i in I0 with the platelet-poor plasma.
Measurements of platelet mobility were made in a horizontal capillary apparatus with platinum electrodes using the technique described by Hampton and Mitchell (I966a In the first 20 patients the platelets were exposed to ADP and to noradrenaline and matched control subjects were also studied: the detailed results have been described previously (Hampton and Mitchell, I966c) . The platelets of the remaining I4 patients were exposed only to ADP. Fig. i ' Patients with abnormal coronary angiograms Eight of the patients studied were found to have diseased coronary arteries. Of these, 7 had platelets which were abnormally sensitive to ADP but normally sensitive to noradrenaline. In 6 of these patients the maximum * platelet mobility was induced by o.oos ,ug/ml of ADP, and in the other maximum mobility was induced by o ooos [ug/ml. The platelets of the eighth patient showed normal sensitivity to ADP, maximum mobility being induced by o.os ,ug/ml. In Fig. 2 The only patient whose platelets were normal but whose coronary angiograms were abnormal was a woman aged 49: her left coronary system was entirely normal but her right coronary artery showed mild irregularities.
Patients with normal coronary angiograms Fig. 3 shows the platelet response to ADP of 4 patients whose coronary angiograms were normal. In 3 of these patients the platelet response was normal, maximum mobility being induced by oo5 ,ug/ml; the stippled area in Fig. 3 includes the mobility curves of these patients. One patient with normal coronary angiograms had platelets that were abnormally sensitive to ADP and the response of these platelets is shown separately. Fig. 4 shows the response to ADP and disease is to study groups of subjects who are noradrenaline of the 22-year-old daughter of known to be more liable to develop it than the a man who died of a myocardial infarction at general population. Patients with hyperlipi-the age of 45: 0o05 o tg/ml of noradrenaline daemia are known to have a high risk of myo-increased platelet mobility to i6 per cent cardial infarction, and such patients do have above the initial level, which approximates to platelets that are abnormally sensitive to ADP the maximum mobility that would be expected (Hampton and Mitchell, I966c) . Another (Hampton and Mitchell, I966d) . Incubation group of subjects at risk are the relatives of with o-oos and o0os ,ug/ml of ADP induced a young patients with myocardial infarctions 2 per cent and a 4 per cent increase, respec- (Deutscher, Ostrander, and Epstein, I970) . tively, so by definition the response of the Platelet electrophoretic behaviour was platelets to ADP was normal: but it seems therefore investigated in 29 close relatives of likely that the maximum mobility would have I4 patients who had developed clinical mani-been induced by a concentration of ADP festations of arterial disease before the age of somewhere between o oos and 0o05 jig/ml, as 45. Of these 14 patients, I3 had had well-indicated by the dotted line in Fig. 4 myocardial infarction at the age of 27; 5 were sibs (4 male and i female); 9 were children; and 2 were children of sibs whose platelets were abnormal. Of the I2 subjects whose platelets were normal, one was a sib (male), ,8 were children, and 3 were children of sibs whose platelets were abnormal. - Table 2 shows that there were no significant differences between the subjects with normal and abnormal platelets in terms of serum levels of cholesterol or triglycerides; there were also no differences in the frequency of <,abnormal lipoprotein electrophoresis. Two of the children studied were of particular interest Three subjects had platelets which were abnormally sensitive to ADP, o oo5 pg/mI inducing a larger increase in mobility than o0os ,ug/ml. Each of these subjects was studied on at least three occasions, and the platelets were found to be abnormally sensitive to ADP each time. On at least one occasion the platelet sensitivity to noradrenaline was investigated and shown to be normal, thus excluding the possibility of the nonspecific increase in platelet sensitivity characteristic of any acute illness. Two of these subjects (a 28-year-old physician and a 22-year-old medical student)
were apparently completely healthy; the third (a 48-year-old ambulance driver) was admitted to hospital with a peptic ulcer. None of these 3 had a family history of premature vascular disease. It seems unlikely that all the relatives of patients with myocardial infarctions whose platelets were found to be abnormally sensitive to ADP will develop arterial disease early in life, and the value of platelet electrophoretic behaviour in the identification of individual subjects particularly at risk can only be determined by following for a prolonged period subjects whose platelets have been studied. If the platelet abnormality does precede the development of arterial disease then it might be expected that individuals with abnormal platelets would sometimes be encountered unexpectedly: in fact this occurred 3 times in I07 subjects whose platelets were expected to be normal and who were being studied for other purposes. A much larger group must be studied before the frequency of 'abnormal' platelet behaviour can be established, but it does seem that 'abnormal' platelets are found more often in the close relatives of young men with myocardial infarctions than in the general population (Table 3) .
Observations of platelet electrophoretic behaviour appear to provide better discrimination between patients with arterial disease and healthy subjects than do measurements separate 'normal' and 'abnormal' platelet behaviour according to the mobility change induced by o-oos and o0os tug/ml of ADP. Though it is possible that there are two populations, one in which maximum platelet mobility is induced by ADP 005 oLg/ml ('normal') and another in which maximum mobility is induced by ADP o.oos ,ug/ml ('abnormal') , it seems much more likely that there is a continuous variation in the concentration of ADP required to induce maximum platelet mobility within the total population. It is not practicable to construct for each individual detailed mobility response curves with many concentrations of ADP and noradrenaline, because the technique is tedious and time-consuming, and relatively large volumes of blood are required. Clarification of the lipid abnormality responsible for the increased platelet sensitivity to ADP may lead to a simpler and more quantitative technique for the study of larger groups of subjects, and experiments to this end are in progress.
